Search results


Therapeutic Response

Precision oncology relationships indicating that patients with listed biomarkers and diagnosed cancer type may be sensitive to the listed therapies.

Filter by organization:
Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (1) KRAS p.G12C Non-Small Cell Lung Cancer Adagrasib
EMA (2) FDA (2) HSE (2) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Afatinib
EMA (3) FDA (2) HSE (2) v::ALK Non-Small Cell Lung Cancer Alectinib
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
EMA (1) FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab
EMA (1) FDA (2) HSE (2) PML::RARA APL with PML-RARA Arsenic trioxide
FDA (2) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (1) ABL1 p.T315I, BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
EMA (1) FDA (1) HSE (2) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab
EMA (1) FDA (1) HSE (2) v::ALK Non-Small Cell Lung Cancer Atezolizumab
FDA (1) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
FDA (1) BRAF p.V600K Melanoma Atezolizumab, Cobimetinib, Vemurafenib
EMA (1) FDA (1) PDGFRA p.D842V Gastrointestinal Stromal Tumor Avapritinib
EMA (2) FDA (2) HSE (1) BRAF p.V600E Melanoma Binimetinib, Encorafenib
EMA (2) FDA (2) HSE (1) BRAF p.V600K Melanoma Binimetinib, Encorafenib
EMA (2) FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib
EMA (1) FDA (2) CD19 + Acute Lymphoid Leukemia Blinatumomab
EMA (5) FDA (1) HSE (3) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
EMA (3) FDA (2) HSE (1) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
FDA (1) CD30 + Anaplastic Large Cell Lymphoma Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
FDA (1) CD30 + Anaplastic Large Cell Lymphoma Brentuximab vedotin
EMA (2) FDA (1) HSE (2) v::ALK Non-Small Cell Lung Cancer Brigatinib
FDA (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Capmatinib
EMA (1) FDA (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Capmatinib
FDA (1) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
FDA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab
EMA (2) FDA (1) HSE (1) v::ALK Non-Small Cell Lung Cancer Ceritinib
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab
EMA (1) FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
EMA (1) FDA (1) HSE (1) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
EMA (1) FDA (1) HSE (1) BRAF p.V600K Melanoma Cobimetinib, Vemurafenib
EMA (2) FDA (1) HSE (1) v::ALK Non-Small Cell Lung Cancer Crizotinib
EMA (1) FDA (1) v::ROS1 Non-Small Cell Lung Cancer Crizotinib
EMA (1) FDA (1) v::ALK Anaplastic Large Cell Lymphoma Crizotinib
EMA (1) FDA (1) v::ALK Inflammatory Myofibroblastic Tumor Crizotinib
EMA (1) FDA (1) HSE (1) BRAF p.V600E Melanoma Dabrafenib
EMA (4) FDA (4) HSE (2) BRAF p.V600E Melanoma Dabrafenib, Trametinib
EMA (4) FDA (4) HSE (2) BRAF p.V600K Melanoma Dabrafenib, Trametinib
EMA (2) FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib
FDA (2) BRAF p.V600E Anaplastic Thyroid Cancer Dabrafenib, Trametinib
FDA (2) BRAF p.V600E Any solid tumor Dabrafenib, Trametinib
EMA (1) FDA (2) BRAF p.V600E Low-Grade Glioma, NOS Dabrafenib, Trametinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Dacomitinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Dacomitinib
FDA (3) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
FDA (3) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
FDA (2) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
EMA (1) FDA (1) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
EMA (1) FDA (1) MSI-H Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
EMA (1) FDA (1) dMMR Endometrial Carcinoma Dostarlimab
FDA (1) dMMR Any solid tumor Dostarlimab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
EMA (1) FDA (1) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel
EMA (1) FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant
FDA (1) IDH2 p.R140Q Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R140L Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R140G Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R140W Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172K Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172M Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172G Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172S Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172W Acute Myeloid Leukemia Enasidenib
EMA (1) FDA (1) HSE (1) v::ROS1 Non-Small Cell Lung Cancer Entrectinib
EMA (1) FDA (1) HSE (1) v::NTRK1 Any solid tumor Entrectinib
EMA (1) FDA (1) HSE (1) v::NTRK2 Any solid tumor Entrectinib
EMA (1) FDA (1) HSE (1) v::NTRK3 Any solid tumor Entrectinib
EMA (1) FDA (1) HSE (1) FGFR3 p.R248C Bladder Urothelial Carcinoma Erdafitinib
EMA (1) FDA (1) HSE (1) FGFR3 p.S249C Bladder Urothelial Carcinoma Erdafitinib
EMA (1) FDA (1) HSE (1) FGFR3 p.G370C Bladder Urothelial Carcinoma Erdafitinib
EMA (1) FDA (1) HSE (1) FGFR3 p.Y373C Bladder Urothelial Carcinoma Erdafitinib
EMA (1) FDA (1) HSE (1) FGFR3::TACC3 Bladder Urothelial Carcinoma Erdafitinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
EMA (1) FDA (1) ER positive Invasive Breast Carcinoma Fulvestrant
FDA (1) PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (1) FDA (1) FGFR2::v Intrahepatic Cholangiocarcinoma Futibatinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Gefitinib
FDA (2) CD33 + Acute Lymphoid Leukemia Gemtuzumab ozogamicin
FDA (1) FLT3-ITD Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835Y Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835A Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835E Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835H Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835N Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835S Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835V Acute Lymphoid Leukemia Gilteritinib
FDA (2) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
EMA (2) FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
FDA (2) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
EMA (1) FDA (1) PDGFRA rearrangements Myelodysplastic Syndromes Imatinib
EMA (1) FDA (1) PDGFRB rearrangements Myelodysplastic Syndromes Imatinib
FDA (1) KIT p.D816V Aggressive Systemic Mastocytosis Imatinib
EMA (1) FDA (1) FIP1L1::PDGFRA Chronic Eosinophilic Leukemia, NOS Imatinib
EMA (2) FDA (1) HSE (2) CD117 + Gastrointestinal Stromal Tumor Imatinib
FDA (1) FIP1L1::PDGFRA Gastrointestinal Stromal Tumor Imatinib
FDA (1) FGFR2::v Cholangiocarcinoma Infigratinib
EMA (1) FDA (1) HSE (1) CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
EMA (4) FDA (2) HSE (2) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
EMA (2) FDA (2) HSE (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) HSE (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) HSE (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (2) IDH1 p.R132C Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132G Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132H Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132L Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132S Acute Myeloid Leukemia Ivosidenib
EMA (1) FDA (1) IDH1 p.R132C Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (1) IDH1 p.R132G Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (1) IDH1 p.R132H Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (1) IDH1 p.R132L Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (1) IDH1 p.R132S Acute Myeloid Leukemia Azacitidine, Ivosidenib
FDA (1) IDH1 p.R132C Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132G Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132H Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132L Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132S Myelodysplastic Syndromes Ivosidenib
EMA (1) FDA (1) HSE (1) IDH1 p.R132C Cholangiocarcinoma Ivosidenib
EMA (1) FDA (1) HSE (1) IDH1 p.R132G Cholangiocarcinoma Ivosidenib
EMA (1) FDA (1) HSE (1) IDH1 p.R132H Cholangiocarcinoma Ivosidenib
EMA (1) FDA (1) HSE (1) IDH1 p.R132L Cholangiocarcinoma Ivosidenib
EMA (1) FDA (1) HSE (1) IDH1 p.R132S Cholangiocarcinoma Ivosidenib
EMA (1) FDA (1) HSE (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
FDA (1) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) HSE (2) v::NTRK1 Any solid tumor Larotrectinib
EMA (1) FDA (1) HSE (2) v::NTRK2 Any solid tumor Larotrectinib
EMA (1) FDA (1) HSE (2) v::NTRK3 Any solid tumor Larotrectinib
FDA (1) 5q deletion Myelodysplastic Syndromes Lenalidomide
EMA (2) FDA (1) HSE (2) v::ALK Non-Small Cell Lung Cancer Lorlatinib
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine
EMA (1) FDA (1) HSE (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835Y Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835A Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835E Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835H Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835N Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835S Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835V Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.I836del Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) CDK12 oncogenic variants Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Mobocertinib
FDA (1) HER2-positive Invasive Breast Carcinoma Neratinib
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib
FDA (3) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
FDA (3) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
FDA (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
EMA (1) FDA (2) HSE (2) BRCA1 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 pathogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) HRD Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) HRD High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) HRD Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (2) FDA (2) HSE (1) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (2) FDA (2) HSE (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 pathogenic variants Pancreatic Adenocarcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 pathogenic variants Pancreatic Adenocarcinoma Olaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) ATM pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) ATM oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BARD1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BARD1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRIP1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRIP1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CDK12 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CDK12 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) FANCL pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) FANCL oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) PALB2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) PALB2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51B pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51B oncogenic variants Prostate Adenocarcinoma Talazoparib
FDA (1) RAD51C pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51C oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51D pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51D oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD54L pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD54L oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) IDH1 p.R132C Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132G Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132H Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132L Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132S Acute Myeloid Leukemia Olutasidenib
EMA (2) FDA (3) HSE (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib
EMA (2) FDA (3) HSE (1) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
EMA (1) FDA (1) HSE (1) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab
EMA (1) FDA (1) HSE (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed
EMA (1) FDA (1) HSE (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (2) HSE (2) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Pembrolizumab
FDA (1) dMMR Any solid tumor Pembrolizumab
FDA (1) MSI-H Any solid tumor Pembrolizumab
EMA (1) FDA (1) HSE (1) dMMR Colorectal Adenocarcinoma Pembrolizumab
EMA (1) FDA (1) HSE (2) MSI-H Colorectal Adenocarcinoma Pembrolizumab
EMA (1) FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
FDA (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) HSE (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Pembrolizumab
FDA (1) MSI-L Endometrial Carcinoma Lenvatinib, Pembrolizumab
FDA (1) pMMR Endometrial Carcinoma Pembrolizumab
EMA (1) FDA (1) MSI-H Endometrial Carcinoma Pembrolizumab
FDA (1) TMB-H (>= 10 mutations / Mb) Any solid tumor Pembrolizumab
FDA (1) HSE (4) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
FDA (1) FGFR2::v Cholangiocarcinoma Pemigatinib
FDA (1) FGFR2 rearrangements Cholangiocarcinoma Pemigatinib
FDA (1) FGFR1 rearrangements Myeloid/Lymphoid Neoplasms Pemigatinib
EMA (4) FDA (2) HSE (3) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HSE (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (1) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (4) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (1) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (1) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
EMA (1) FDA (1) HSE (1) ABL1 p.T315I Chronic Myelogenous Leukemia Ponatinib
EMA (1) FDA (1) v::RET Non-Small Cell Lung Cancer Pralsetinib
FDA (1) v::RET Papillary Thyroid Cancer Pralsetinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
EMA (1) FDA (1) v::ROS1 Non-Small Cell Lung Cancer Repotrectinib
EMA (1) FDA (1) v::NTRK1 Any solid tumor Repotrectinib
EMA (1) FDA (1) v::NTRK2 Any solid tumor Repotrectinib
EMA (1) FDA (1) v::NTRK3 Any solid tumor Repotrectinib
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (1) HSE (2) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HSE (2) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HSE (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HSE (4) CD20 + Non-Hodgkin Lymphoma Rituximab
FDA (1) HSE (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
EMA (1) FDA (1) HSE (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
FDA (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Burkitt Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Mature B-Cell Neoplasms Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Chronic Lymphocytic Leukemia Cyclophosphamide, Fludarabine, Rituximab
FDA (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib
EMA (1) FDA (1) HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) v::RET Non-Small Cell Lung Cancer Selpercatinib
FDA (1) RET oncogenic variants Medullary Thyroid Cancer Selpercatinib
FDA (1) v::RET Anaplastic Thyroid Cancer Selpercatinib
EMA (1) FDA (1) v::RET Any solid tumor Selpercatinib
EMA (1) FDA (1) KRAS p.G12C Non-Small Cell Lung Cancer Sotorasib
EMA (1) FDA (1) HSE (1) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
EMA (1) FDA (1) HSE (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
EMA (1) FDA (1) HSE (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Tepotinib
EMA (1) FDA (1) HSE (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Tepotinib
EMA (1) FDA (1) BRAF p.V600E Melanoma Trametinib
EMA (1) FDA (1) BRAF p.V600K Melanoma Trametinib
EMA (2) FDA (1) HSE (4) HER2-positive Invasive Breast Carcinoma Trastuzumab
FDA (1) HER2-positive Gastrointestinal Stromal Tumor Trastuzumab
EMA (1) FDA (1) HSE (1) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (1) HSE (1) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (1) ERBB2 oncogenic variants Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) FDA (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
FDA (1) HER2-positive Any solid tumor Trastuzumab deruxtecan
EMA (1) FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
EMA (1) FDA (1) HSE (1) BRAF p.V600E Melanoma Vemurafenib
FDA (1) BRAF p.V600E Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease Vemurafenib
FDA (1) BRAF p.V600K Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease Vemurafenib
FDA (1) EZH2 p.Y646N Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646F Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646H Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646S Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646C Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.A862G Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.A692V Follicular Lymphoma Tazemetostat
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATM pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATM oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATR oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CDK12 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATR pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) FANCA oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CHEK2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CHEK2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) FANCA pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MLH1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) PALB2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) PALB2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MLH1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MRE11 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) RAD51C pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) RAD51C oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MRE11 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) NBN oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) NBN pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) TSC1 oncogenic variants Renal Angiomyolipoma Everolimus
FDA (1) TSC2 oncogenic variants Renal Angiomyolipoma Everolimus
FDA (1) TSC1 oncogenic variants Anaplastic Thyroid Cancer Everolimus
FDA (1) TSC2 oncogenic variants Anaplastic Thyroid Cancer Everolimus
FDA (1) CDK12 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
EMA (3) FDA (2) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib
EMA (3) FDA (2) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib
EMA (1) FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
EMA (1) FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
EMA (1) FDA (1) FOLR1 positive Ovarian Epithelial Tumor Mirvetuximab soravtansine
EMA (1) FDA (1) FOLR1 positive High-Grade Serous Fallopian Tube Cancer Mirvetuximab soravtansine
EMA (1) FDA (1) FOLR1 positive Peritoneal Serous Carcinoma Mirvetuximab soravtansine
FDA (1) BRAF rearrangements Low-Grade Glioma, NOS Tovorafenib
FDA (1) v::BRAF Low-Grade Glioma, NOS Tovorafenib
FDA (1) BRAF p.V600E Low-Grade Glioma, NOS Tovorafenib
FDA (1) BRAF p.V600K Low-Grade Glioma, NOS Tovorafenib
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed
FDA (1) KRAS p.G12C Colorectal Adenocarcinoma Adagrasib, Cetuximab
EMA (1) FDA (1) IDH1 p.R132C Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132G Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132H Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132L Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132S Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172K Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172M Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172G Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172S Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172W Astrocytoma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132C Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132G Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132H Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132L Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH1 p.R132S Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172K Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172M Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172G Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172S Oligodendroglioma Vorasidenib
EMA (1) FDA (1) IDH2 p.R172W Oligodendroglioma Vorasidenib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
EMA (4) FDA (2) HSE (2) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) MSI-H Colorectal Adenocarcinoma Nivolumab
FDA (1) dMMR Colorectal Adenocarcinoma Nivolumab
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab
EMA (1) FDA (1) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
EMA (1) FDA (1) HER2-positive Intraductal Papillary Neoplasm of the Bile Duct Zanidatamab
EMA (1) FDA (1) HER2-positive Intracholecystic Papillary Neoplasm Zanidatamab
EMA (1) FDA (1) HER2-positive Cholangiocarcinoma Zanidatamab
FDA (1) v::NRG1 Non-Small Cell Lung Cancer Zenocutuzumab
FDA (1) v::NRG1 Pancreatic Adenocarcinoma Zenocutuzumab
FDA (1) v::ALK Non-Small Cell Lung Cancer Ensartinib
FDA (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
FDA (1) t(KMT2A;v) Acute Lymphoid Leukemia Revumenib
FDA (1) t(KMT2A;v) Acute Myeloid Leukemia Revumenib
FDA (1) t(KMT2A;v) Burkitt Lymphoma Revumenib
FDA (1) t(KMT2A;v) Acute Leukemias of Ambiguous Lineage Revumenib
EMA (1) CD30 + Hodgkin Lymphoma Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine
EMA (2) HSE (3) CD30 + Hodgkin Lymphoma Brentuximab vedotin
EMA (1) HSE (1) CD30 + Cutaneous T-cell Lymphoma Brentuximab vedotin
EMA (1) HSE (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (1) HSE (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (1) HSE (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
EMA (1) HSE (1) BCR::ABL1, CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
EMA (3) CD22 + Chronic Myeloid Leukemia, BCR-ABL1+ Bosutinib
EMA (1) HSE (1) v::RET Medullary Thyroid Cancer Vandetanib
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
EMA (3) HSE (2) HER2-positive Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (3) ERBB2 amplification Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Oxaliplatin
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Gefitinib
EMA (1) HSE (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Afatinib
EMA (2) HSE (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) HSE (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) HSE (1) HER2-positive Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (1) HER2-positive Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
EMA (1) HER2-positive Esophagogastric Adenocarcinoma Cisplatin, Fluorouracil, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Cisplatin, Fluorouracil, Trastuzumab
EMA (2) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
EMA (2) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
EMA (1) PDGFRA rearrangements Myeloproliferative Neoplasm Imatinib
EMA (1) PDGFRB rearrangements Myeloproliferative Neoplasm Imatinib
EMA (1) HSE (1) BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
EMA (1) HSE (1) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
EMA (1) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Durvalumab
EMA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab
EMA (1) pMMR Endometrial Carcinoma Carboplatin, Durvalumab, Olaparib, Paclitaxel
EMA (1) MSI-H Endometrial Carcinoma Dostarlimab
EMA (1) HSE (2) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) HSE (1) CD274 amplification, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) HSE (2) PD-L1 (CPS) >= 10 Bladder Urothelial Carcinoma Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 >= 50% Head and Neck Squamous Cell Carcinoma Pembrolizumab
EMA (1) dMMR Endometrial Carcinoma Pembrolizumab
EMA (1) MSI-H Esophagogastric Adenocarcinoma Pembrolizumab
EMA (1) dMMR Esophagogastric Adenocarcinoma Pembrolizumab
EMA (1) MSI-H Gastrointestinal Stromal Tumor Pembrolizumab
EMA (1) dMMR Gastrointestinal Stromal Tumor Pembrolizumab
EMA (1) MSI-H Cholangiocarcinoma Pembrolizumab
EMA (1) dMMR Cholangiocarcinoma Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Pembrolizumab
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
EMA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab emtansine
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Cemiplimab
EMA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
EMA (1) pMMR Endometrial Carcinoma Durvalumab, Olaparib
EMA (1) FGFR2 rearrangements Intrahepatic Cholangiocarcinoma Futibatinib
EMA (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
EMA (1) CD20 + Diffuse Large B-Cell Lymphoma Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
EMA (1) CD20 + Non-Hodgkin Lymphoma Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
EMA (1) CD20 + Burkitt Lymphoma Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
EMA (2) BRAF p.V600K Non-Small Cell Lung Cancer Dabrafenib, Trametinib
EMA (1) CD33 + Acute Myeloid Leukemia Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
EMA (1) HSE (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) ER positive, ERBB2 amplification Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (2) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
EMA (2) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Pemetrexed
EMA (1) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
EMA (1) HSE (1) PD-L1 >= 1% Bladder Urothelial Carcinoma Nivolumab
EMA (2) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Ipilimumab, Nivolumab
EMA (1) HSE (2) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Esophageal Adenocarcinoma Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Esophageal Adenocarcinoma Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Esophagogastric Adenocarcinoma Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Esophagogastric Adenocarcinoma Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Nivolumab, Oxaliplatin
EMA (1) PD-L1 < 1% Melanoma Nivolumab, Relatlimab
EMA (1) HSE (1) FGFR2::v Intrahepatic Cholangiocarcinoma Elacestrant
EMA (1) HSE (1) FGFR2 rearrangements Intrahepatic Cholangiocarcinoma Elacestrant
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) v::RET Papillary Thyroid Cancer Selpercatinib
EMA (1) RET p.M918T Medullary Thyroid Cancer Selpercatinib
EMA (1) 5q deletion Myeloproliferative Neoplasm Lenalidomide
EMA (1) HSE (1) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
EMA (1) BRAF p.V600E High-Grade Glioma, NOS Dabrafenib, Trametinib
EMA (3) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
EMA (2) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
EMA (1) HSE (1) BRAF p.V600K Melanoma Dabrafenib
EMA (1) HSE (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib
EMA (2) HSE (2) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib
EMA (3) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
EMA (1) HSE (3) PD-L1 >= 5% Bladder Urothelial Carcinoma Atezolizumab
EMA (2) HSE (6) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) Wild type ALK Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) HSE (3) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) HSE (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
EMA (1) ER positive, HER2-positive, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Capecitabine, Lapatinib
EMA (1) ER positive, ERBB2 amplification, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
EMA (2) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
EMA (1) HSE (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
EMA (1) HSE (1) TP53 somatic variants Chronic Lymphocytic Leukemia Venetoclax
EMA (1) HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Venetoclax
EMA (2) HSE (1) 17p deletion Chronic Lymphocytic Leukemia Venetoclax
EMA (1) HSE (1) Wild type TP53 Chronic Lymphocytic Leukemia Venetoclax
EMA (1) HSE (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Dacomitinib
EMA (1) HSE (1) FLT3-ITD Acute Myeloid Leukemia Gilteritinib
EMA (1) HSE (1) FLT3 p.D835Y Acute Myeloid Leukemia Gilteritinib
EMA (1) HSE (1) BRAF p.V600K Melanoma Vemurafenib
EMA (1) HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Idelalisib, Rituximab
EMA (1) HSE (1) TP53 somatic variants Chronic Lymphocytic Leukemia Idelalisib, Rituximab
EMA (1) HSE (1) 17p deletion Chronic Lymphocytic Leukemia Idelalisib, Rituximab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pemetrexed, Tislelizumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pemetrexed, Tislelizumab
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) HSE (1) FGFR2::BICC1 Bladder Urothelial Carcinoma Erdafitinib
EMA (1) HSE (1) FGFR2::CASP7 Bladder Urothelial Carcinoma Erdafitinib
EMA (1) HSE (1) FGFR3::BAIAP2L1 Bladder Urothelial Carcinoma Erdafitinib
HSE (1) TP53 somatic variants Chronic Lymphocytic Leukemia Zanubrutinib
HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Zanubrutinib
HSE (1) 17p deletion Chronic Lymphocytic Leukemia Zanubrutinib
HSE (1) TP53 somatic variants Chronic Lymphocytic Leukemia Acalabrutinib
HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Acalabrutinib
HSE (1) 17p deletion Chronic Lymphocytic Leukemia Acalabrutinib
HSE (1) TP53 somatic variants Chronic Lymphocytic Leukemia Ibrutinib
HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Ibrutinib
FDA (1) HSE (1) 17p deletion Chronic Lymphocytic Leukemia Ibrutinib
HSE (1) CD30 + Hodgkin Lymphoma Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide
HSE (1) CD33 + Acute Lymphoid Leukemia Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
HSE (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HSE (1) CD30 +, HER2-negative Hodgkin Lymphoma Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Pembrolizumab
HSE (1) BCR::ABL1 Acute Lymphoid Leukemia Blinatumomab
HSE (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab
HSE (2) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine
HSE (2) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab
HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Nivolumab
EMA (1) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
HSE (2) HER2-negative Invasive Breast Carcinoma Bevacizumab, Paclitaxel
HSE (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
HSE (2) ER positive Invasive Breast Carcinoma Tamoxifen
HSE (2) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole
HSE (2) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole
HSE (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole
HSE (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (2) ER negative Invasive Breast Carcinoma Fulvestrant
HPRA (3) HSE (3) ER positive, PR positive Invasive Breast Carcinoma Letrozole
HPRA (3) HSE (3) ER positive Invasive Breast Carcinoma Letrozole
HPRA (3) HSE (3) PR positive Invasive Breast Carcinoma Letrozole
HSE (1) ER positive, PR positive Invasive Breast Carcinoma Exemestane
HPRA (1) HSE (1) ER positive Invasive Breast Carcinoma Exemestane
HSE (1) PR positive Invasive Breast Carcinoma Exemestane
HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
HSE (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
HSE (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Nivolumab, Oxaliplatin
HSE (2) FLT3-ITD Acute Myeloid Leukemia Midostaurin
HSE (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
HSE (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
HSE (1) CD20 + Non-Hodgkin Lymphoma Carboplatin, Etoposide, Ifosfamide, Rituximab
HSE (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine
HSE (1) CD20 + Diffuse Large B-Cell Lymphoma Gemcitabine, Oxaliplatin, Rituximab
HSE (1) CD20 + Non-Hodgkin Lymphoma Gemcitabine, Oxaliplatin, Rituximab
HSE (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine
HSE (1) CD30 + Hodgkin Lymphoma Bendamustine, Brentuximab vedotin
HSE (1) CD20 + Follicular Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
HSE (1) CD20 + Follicular Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
HSE (1) CD20 + Follicular Lymphoma Chlorambucil, Mitoxantrone, Prednisolone, Rituximab
HSE (1) CD20 + Follicular Lymphoma Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab
HSE (4) CD20 + Follicular Lymphoma Rituximab
HPRA (3) HSE (1) ER positive Invasive Breast Carcinoma Anastrozole
HPRA (3) HSE (1) PR positive Invasive Breast Carcinoma Anastrozole
HPRA (3) HSE (1) ER positive, PR positive Invasive Breast Carcinoma Anastrozole
HPRA (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole
HPRA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole
HPRA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole
FDA (1) v::ROS1 Non-Small Cell Lung Cancer Taletrectinib
FDA (1) c-Met >= 50% Lung Non-Squamous Non-Small Cell Carcinoma Telisotuzumab Vedotin
FDA (1) KRAS p.G12C Low-Grade Serous Ovarian Cancer Avutometinib, Defactinib
FDA (1) KRAS p.G12V Low-Grade Serous Ovarian Cancer Avutometinib, Defactinib
FDA (2) t(15;17) APL with PML-RARA Arsenic trioxide
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.T790M Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 20 (Insertion) Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Sunvozertinib
FDA (1) ERBB2 TKD activating variants Lung Non-Squamous Non-Small Cell Carcinoma Zongertinib
EMA (1) ER positive, HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Docetaxel, Nivolumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) H3-3A p.K27M Diffuse Midline Glioma Dordaviprone
FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Imlunestrant
FDA (1) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib
EMA (1) FDA (1) FLT3-ITD Acute Myeloid Leukemia Quizartinib
EMA (1) FDA (1) HSE (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Quizartinib
EMA (1) FDA (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Idarubicin, Quizartinib
FDA (1) NPM1 p.W288Cfs*12 Acute Myeloid Leukemia Ziftomenib
FDA (1) ERBB2 TKD activating variants Lung Non-Squamous Non-Small Cell Carcinoma Sevabertinib
FDA (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan
FDA (1) NPM1 p.W288Cfs*12 Acute Myeloid Leukemia Revumenib
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) NPM1 p.W288Cfs*12 Acute Lymphoid Leukemia Revumenib
FDA (1) NPM1 p.W288Cfs*12 Burkitt Lymphoma Revumenib
FDA (1) NPM1 p.W288Cfs*12 Acute Leukemias of Ambiguous Lineage Revumenib